Mirfeel Korea's hand sanitizer contained benzene and had testing failures; FDA also says food-pouch packaging misbranded.
What happened
FDA laboratory testing of a batch in U.S. distribution found benzene at 5 to 6 ppm in MOISTURIZING HAND SANITIZER Peppermint Scented made at Mirfeel's facility. FDA also reviewed records the firm submitted after an August 3, 2021 request and found violations of current good manufacturing practice (CGMP). FDA cited the 1.01 ounce hand sanitizer containers as misbranded because they resemble food pouches.
What FDA found
FDA found benzene at 5 to 6 ppm in a hand sanitizer batch made at the facility, showing quality assurance was not working under CGMP.
FD&C Act section 501(a)(2)(B) (21 U.S.C. 351(a)(2)(B))The firm did not perform appropriate finished-product testing, including identity and strength of the active ingredient, before releasing hand sanitizer.
21 CFR 211.165(a)The firm relied on supplier certificates of analysis without doing at least one identity test for each incoming component lot and without verifying supplier test reliability.
21 CFR 211.84(d)(1) and 21 CFR 211.84(d)(2)The firm lacked an adequate stability program and did not provide expiry dates; stability tests covered only appearance and physical characteristics.
21 CFR 211.166(a)The 1.01 ounce hand sanitizer containers resemble food pouches, which FDA says can mislead consumers and risk accidental ingestion.
FD&C Act section 502(i)(1) (21 U.S.C. 352(i)(1))
What FDA wants
FDA tells Mirfeel to respond in writing within 15 working days with corrective actions, including a benzene investigation, raw material and batch lists, complete batch records, impurity testing for all unexpired U.S. batches, and a stability-program CAPA. FDA also strongly recommends a qualified CGMP consultant.
Who should pay attention
- brands and retailers selling Mirfeel hand sanitizer
- U.S. importers and distributors of OTC hand sanitizer
- hand sanitizer ingredient suppliers and contract manufacturers
This is a summary. Read the original letter on fda.gov.